Executive summary
Burnout at chief executive level is widely reported and poorly addressed, and the reporting is less solid than the volume of it suggests. In a clinical review of 298 senior executives and CEOs seen at CEREVITY between January 2025 and August 2026, 71 percent met criteria for significant burnout on structured assessment, 63 percent reported deliberately concealing the severity from their boards, and 49 percent said the strain had already affected their decision quality. The median interval from clear recognition of the problem to a first clinical session was 19 months. This paper does three things: it states what the prevalence figures actually measure, it quantifies the concealment, and it separates the interventions with evidence behind them from the ones without.
The chief executive is evaluated continuously by a board, depended upon by a company, and rewarded structurally for appearing in control, which puts strain in direct tension with the requirements of the seat.
Concealment from the board is a rational reading of that structure rather than a failure of candour, and because external performance usually holds while the strain rises, the concealment keeps being reinforced.
A clinical route that is structurally separate from the organisation and the board, chosen on the basis of what the evidence supports rather than what is easiest to announce.
Strain is addressed while the executive still has range, instead of surfacing as an exit recorded under a reason that has nothing to do with what happened.
The problemThe reported numbers are real, but they do not measure what people think§
The widely circulated CEO burnout figures come almost entirely from one organisation, and their meaning depends on a threshold that is usually dropped in transmission. In the largest available survey, 1,537 US chief executives fielded between 2 and 16 June 2025, 68 percent reported feeling burned out or emotionally exhausted at least occasionally over the previous three months.02 At least occasionally is a low bar. In a separate survey of 495 small-business CEOs fielded in May 2025, the same question produced 94 percent reporting any symptoms across the year and 32 percent reporting them frequently or daily.03 Those are not three findings. They are one question read at three cut-points. No probability-based estimate of CEO burnout prevalence exists that we could locate; every available figure comes from a vendor survey of a self-selected membership panel, and that limitation belongs in the open rather than in a footnote.
The definitional position matters as much as the arithmetic. Burnout is included in ICD-11 as an occupational phenomenon and is explicitly not classified as a medical condition, defined as a syndrome resulting from chronic workplace stress that has not been successfully managed, characterised by exhaustion, mental distance or cynicism toward the job, and reduced professional efficacy.04 The originators of the construct describe it as a psychological syndrome emerging as a prolonged response to chronic interpersonal stressors on the job, along the same three dimensions.05 So burnout is not a diagnosis, and a survey asking whether someone has felt burned out is not measuring one. What makes the CEO case distinct is not a higher rate but the structure around disclosure. Boards evaluate results, teams take their cue from the chair, and the strain therefore competes directly with the requirements of the role. The sequence that follows is consistent: performance that still looks acceptable, internal load rising underneath it, and a considered decision not to give the board the full picture.
Of 2,221 CEO departures announced in 2024, 21 were attributed to personal reasons and 537 gave no reason at all. Challenger, Gray and Christmas CEO Turnover Report, full year 2024
The evidenceWhat the research shows§
Two bodies of evidence are used here and kept apart, and in this paper the distinction carries unusual weight because the two are not measuring the same construct. The first is a clinical review of 298 consecutive senior executive and CEO clients seen at CEREVITY between January 2025 and August 2026, a help-seeking sample rather than a population survey, with n and date range attached to every internal figure. The second is published survey research, peer-reviewed work on burnout and cognition, a randomised trial of workplace wellness, and a quasi-experimental study of CEO mortality. Where the external record undercuts a comfortable reading of our own numbers, it is reported.
71%
met criteria for significant burnout on structured clinical assessment
CEREVITY clinical review, n=298, 2025 to 2026
63%
reported deliberately concealing the severity from their boards
CEREVITY clinical review, n=298, 2025 to 2026
49%
said the strain had already affected their decision quality
CEREVITY clinical review, n=298, 2025 to 2026
19 mo
median interval from clear recognition to a first clinical session
CEREVITY clinical review, n=298, 2025 to 2026
Our 71 percent and the survey figures are not comparable, and treating them as mutually confirming would be the wrong reading. The survey figures ask CEOs whether they have felt burned out; ours records whether a clinician judged criteria for significant burnout to be met in someone who had already decided to seek help. Set against the strict end of the survey data, where 32 percent reported burnout frequently or daily,03 our figure is far higher, which is exactly what a clinical sample should look like. Set against the loose end, 68 percent at least occasionally,02 the numbers happen to sit close together and mean entirely different things. The honest summary is that our sample tells you what burnout looks like among CEOs who reach a clinician, and the surveys tell you how many CEOs will use the word about themselves. Neither establishes a population prevalence.
The concealment finding is where the external record is most supportive. In a 2024 survey of more than three thousand employees, HR leaders and CEOs, 81 percent of CEOs agreed or strongly agreed that companies view someone with mental health issues as weak or a burden, a higher share than either HR or employees, and 55 percent of CEOs reported having experienced a mental health issue in the prior year.07 The mechanism on the receiving side is documented too: people hold taken-for-granted beliefs about when speaking up is risky, and those beliefs suppress even pro-organisational disclosure.09 What the concealment costs is also known. Across ten studies analysing more than thirteen thousand secrets, it was the frequency of mind-wandering to a withheld matter, independent of how often it had to be actively concealed, that predicted lower wellbeing.10 Our earlier work on what CEOs withhold from their directors is summarised in what CEOs hide from their boards.
| Indicator | CEREVITY sample (n=298) | External evidence | Source |
|---|---|---|---|
| Met criteria for significant burnout | 71% | 68% of 1,537 CEOs felt burned out at least occasionally; 32% of 495 frequently or daily | CEREVITY01; Vistage02, 03 |
| Concealed the severity from the board | 63% | 81% of surveyed CEOs agree companies view mental health issues as weakness or burden | CEREVITY01; Businessolver07 |
| Said the strain affected decision quality | 49% | Acute stress impaired working memory (g=-.20) and cognitive flexibility (g=-.30) by meta-analysis | CEREVITY01; Shields et al.13 |
| Median delay, recognition to first session | 19 months | 6 to 8 years from onset to first treatment contact for mood disorders, general population | CEREVITY01; Wang et al.17 |
| Whether burnout is a diagnosis | Not applicable | ICD-11 lists burn-out as an occupational phenomenon and explicitly not a medical condition | World Health Organization04 |
| What sustained strain costs physically | Not separately scored | CEO lifespan fell 1.5 years after an industry downturn and rose 2 years under weaker market discipline | Borgschulte et al.06 |
| Whether generic wellness programmes help | Not separately scored | A randomised trial of 32,974 employees found no effect on 27 health outcomes or 3 employment outcomes | Song and Baicker14 |
01, 02 CEREVITY clinical review, n=298, January 2025 to August 2026. Clinical, help-seeking sample; concealment and decision-quality items are self-reported. Not a prevalence estimate.
Vistage CEO Confidence Index, Q2 2025, n=1,537 US CEOs, fielded 2 to 16 June 2025. Vendor survey of its own membership; threshold is at least occasionally over three months.
02, 03 Vistage CEO Confidence Index, Q2 2025, n=1,537 US CEOs, fielded 2 to 16 June 2025. Source of the 68 percent figure.
WSJ and Vistage Small Business CEO Confidence Index, May 2025, n=495, fielded 5 to 12 May 2025. Source of the 94 percent and 32 percent figures. Different sample and recall window from the 68 percent; shown together to expose the threshold effect, not as a matched comparison.
The frameworkA model you can name and own§
Four phases recur in the clinical sample, with delayed care as a consequence of the cycle rather than a stage inside it. The model is descriptive rather than diagnostic, and it is built around the reinforcement problem: because the numbers the board watches have not moved, the decision to withhold keeps being confirmed as correct.
CEREVITY model
The CEO Burnout Cycle
A four-phase description of how a chief executive under sustained load ends up concealing the severity from the people responsible for governing it. Each phase is a judgement about the board rather than a symptom, which is what makes the cycle interruptible without a disclosure.
Sustained demand with limited recovery
Load is high and recovery is compressed, but the executive is performing and the strain reads as the ordinary cost of the seat. Nothing has been concealed because nothing has been named.
Internal strain rising while performance holds
The gap opens between what the numbers show and what the work costs. This is the phase in which the same output is being produced at a materially higher internal price, and it is invisible to every metric the board reviews.
Calculated non-disclosure to the board
A deliberate decision not to give the board the full picture, almost always framed as protecting the company or the confidence of the team rather than protecting the self. Because results have not moved, the decision looks vindicated.
Narrowing of cognitive and emotional range
Judgement gets more conservative or more abrupt, patience shortens, and the executive's available repertoire contracts. In this sample the median lag from recognition to a first session was 19 months.
The clinical objective is to interrupt during phase two or three, while the question is still about disclosure rather than about capacity. The operational insight is that interruption does not require the board to be told anything. It requires one route to care that has no line into the company, the board or the employment record, which means the executive is not choosing between silence and a disclosure to the people who evaluate them.
SCHEMATIC Schematic, not measured data.
Descriptive model derived from patterns observed in the CEREVITY clinical review, n=298, January 2025 to August 2026. The curves are illustrative and carry no units.
By professionHow it presents across roles§
The cycle is one pattern, but what the executive believes is at stake, and how much room they have to be uncertain, changes with the seat. The three groups below are the ones represented in the CEREVITY sample.
First-time CEOs
This group shows the highest isolation and the longest delay in the sample. The reason is specific rather than temperamental: a first-time chief executive has no prior calibration for the role, so they cannot tell which part of the difficulty is the job and which part is them. That ambiguity is resolved almost always in the direction of self-blame, which makes disclosure feel like an admission of unfitness rather than a report on conditions. Every existing relationship also changes at once. The peers who would have been the honest audience are now reports or competitors, and the board is an evaluator from the first meeting. The research on upward communication describes the resulting silence well: people operate on implicit rules about when speaking up is risky, and those rules suppress disclosure even when it would help the organisation.09 Clinically this segment presents with the sharpest imposter-adjacent material and the least developed sense of what normal load looks like at this level. The most useful early intervention is calibration rather than reassurance: telling a first-time CEO that 68 percent of chief executives report feeling burned out at least occasionally does more work than any encouragement, because it converts a private verdict about their adequacy into a description of the seat.02 How executives manage this without visibly stepping back is covered in managing burnout without taking time off.
Individual CEO therapist
Organizational CEREVITY's CEO transition therapy vendor for boards
Experienced and repeat CEOs
Concealment rates are somewhat lower in this group and remain substantial, and that is the finding worth sitting with. Having done the job before does not create a safe channel; it mainly produces someone more skilled at operating without one. Several factors are specific. Reputation now has a longer horizon than any single company, so the perceived cost of a disclosure extends past the current board to future appointments and directorships. The executive also has a track record of having got through it before, which functions as an argument against seeking help rather than for it. And the load has usually been carried long enough that its cost is no longer noticed as unusual. The cognitive picture here is worth stating carefully. A systematic review of 15 studies found burnout associated with declines in executive function, attention and memory while explicitly declining to establish causality,11 and a neurophysiological study of 54 participants found no difference in objective task performance between a burnout group and controls, but greater neural resource allocation to achieve it.12 That is the more precise version of what this segment reports: the same output, at a higher internal price, for longer than anyone around them realises.
Individual therapy for people whose ambition is not the problem
Organizational coaching to therapy referral partnership
Private equity and investor-backed CEOs
This group carries the standard board relationship plus a sponsor with a thesis, a hold period and a replacement option. Reporting is more frequent, the metrics are tighter, and the distance between a disappointing quarter and a conversation about leadership is shorter than in most public companies. The disclosure calculation is correspondingly harsher, because the executive is being assessed not only on results but on whether they remain the right person for a defined plan. Two features distinguish the segment clinically. Strain tends to be organised around a calendar of board and sponsor meetings rather than distributed evenly, producing a recognisable pattern of compressed sleep and narrowed decision-making in the period before each one. And the executive's own equity usually depends on an outcome several years out, which makes stepping back financially as well as professionally expensive. The stigma finding applies with particular force here: 81 percent of surveyed CEOs agreed that companies view someone with mental health issues as weak or a burden.07 A sponsor relationship also removes the ambiguity a public-company chief executive can sometimes hide in, because there is a named partner, a stated plan, and a documented view on whether the current leadership executes it. In this sample that produced the most explicitly strategic concealment of the three groups: not a reluctance to be vulnerable but a timed decision about what to say and when, often described in the language of a negotiation rather than of a feeling. What works clinically is treating the hold period rather than the quarter as the unit of analysis, so the executive can locate their own strain inside the whole plan instead of reading each board meeting as a separate verdict. Sponsor and the private equity leadership strain report.
Individual confidential therapy for owners
Organizational the setting up confidential therapy for company leadership program
The stakesThe cost of inaction§
The first cost is borne by the executive, in the form of strain left untreated for a median of 19 months from the point they clearly recognised it.01 The second is borne by the company and by the board, and it arrives late by design, because everything about the adaptation is built to leave the reviewed metrics undisturbed.
Decision quality, stated carefully
Forty-nine percent of this sample said the strain had already affected their decision quality.01 The external evidence supports the direction while limiting the size of the claim: a meta-analysis found acute stress impaired working memory and cognitive flexibility with small effect sizes of roughly -0.20 and -0.30, and improved response inhibition, so the effect is real, modest and not uniform.13 Applied to a chief executive making a small number of consequential calls, a modest average effect is still worth something, and that is where care for cognitive load in decision-heavy roles belongs.
A documented physical cost
The strongest evidence in this paper is not about mood. Using the staggered passage of state anti-takeover laws and industry-wide distress shocks across 1,605 chief executives of large US public companies, CEO lifespan increased by two years when insulated from market discipline and decreased by 1.5 years following an industry downturn, with exposure to a distress shock during the Great Recession increasing apparent age by one year over the following decade.06 That sample is overwhelmingly male and White and should not be generalised beyond it, but within it the finding is quasi-experimental rather than correlational.
Surfacing at the least controllable moment
Because nothing is disclosed early, what eventually happens is usually involuntary. The departure data is instructive precisely because of what it does not contain: of 2,221 CEO departures announced in 2024, 21 were recorded as personal reasons and 17 as death, while 537 gave no reason at all.16 That is an absence of stated attribution rather than evidence of hidden cause, and it should be read as exactly that. What it does establish is that health is almost never the reason a CEO exit gives.
01, 06, 17 CEREVITY clinical review, n=298, January 2025 to August 2026.
Borgschulte, M. et al. (2025). The Journal of Finance, 1,605 CEOs. Lifespan decreased by 1.5 years in response to an industry-wide downturn. A lifespan effect is not an interval to care; it is placed on this axis for scale only.
Wang, P. S. et al. (2005). National Comorbidity Survey Replication, n=9,282. A different population and interval, shown for scale.
The solutionWhat effective care looks like§
This is where most CEO burnout material becomes unserious, so it is worth being specific about what the evidence actually shows. Generic wellness provision has been tested properly and performed poorly. A cluster-randomised trial across 160 worksites and 32,974 employees found a workplace wellness programme produced no significant effect on 27 self-reported health outcomes, 10 clinical markers, 38 spending and utilisation measures, or 3 employment outcomes.14 A cross-sectional study of 46,336 workers across 233 organisations found that participants in individual-level interventions such as resilience training, mindfulness and wellbeing apps had the same levels of mental wellbeing as non-participants.15 Neither result proves such programmes cannot work, and the second is not a trial, but together they make one thing clear: announcing a wellness initiative is not an intervention. The originators of the burnout construct make the same point from the other direction, noting the relative dearth of evaluative research on interventions to treat or prevent it.05
What follows from that is a preference for structure over programming. Care for this population needs to be individual rather than population-level, structurally separate from the company and the board rather than merely described as confidential, delivered by clinicians who understand board and sponsor dynamics well enough that the executive does not spend the first session explaining what a hold period or an audit committee is, and available in formats that survive a chief executive's calendar. CEREVITY is a nationwide network of independent licensed clinicians, matched to the person and delivered by secure video on a fully private-pay basis, with no diagnosis code travelling through an insurer and no record inside the company's systems. Sessions run in three formats and no others: 50-minute therapy sessions for continuity, and 90-minute therapy sessions where an hour keeps interrupting the work.
Where an executive can find one clear block but not a standing weekly appointment, therapy intensives running 3 hours reach in one sitting what would otherwise spread across a quarter. CEREVITY's approach to treatment sets out how clinicians are matched to the pressures of a role rather than to a diagnosis alone. One limitation should be stated plainly rather than left for a reader to notice: no randomised trial of this specific model exists. The claim here is that individual psychotherapy delivered outside the organisation addresses the mechanism this paper documents, which population-level wellness programming demonstrably does not, and that is an argument about fit rather than a claim of proven superiority.
ImplementationHow to put it into practice§
Four steps. The first two are for the chief executive, the second two for the board or sponsor that would rather not encounter this as an unexplained departure.
- 01
Name the concealment, not the mood
Ask directly whether the full severity has been withheld from the board and for how long. It is a more answerable question than any question about how someone is, because the decision was made consciously and can usually be dated to a specific meeting. Sixty-three percent of this sample answered yes.01
- 02
Calibrate against the actual figures, with their thresholds attached
A chief executive treating their own strain as evidence of unfitness is working from a false comparison. Sixty-eight percent of 1,537 CEOs reported feeling burned out or emotionally exhausted at least occasionally, and roughly a third of a separate CEO sample reported it frequently or daily.02, 03 Quoting those figures without their thresholds is what produced the inflated numbers in circulation, and a board-level audience will check.
- 03
For boards: separate the support route from the evaluation route completely
A board cannot be the confidential channel for the person it evaluates, and offering to be one is read as a test. Eighty-one percent of surveyed CEOs agreed that companies view mental health issues as weakness or burden.07 The useful contribution is to fund and make available a route with no reporting line into the company, and then to stay out of it.
- 04
Do not substitute a programme for an intervention
The randomised evidence on generic workplace wellness is close to null, and the individual-level intervention evidence is no better.14, 15 A board that responds to a burned-out chief executive by procuring an app has answered a different question than the one in front of it.
RecommendationsWhere to start§
Clinical
Treat sustained output plus rising concealment as the signal
Neither half is informative alone. Strong results are the expected state, and concealment is invisible unless asked about, so the combination is the thing to watch. The pattern of the same output at a higher internal cost is documented: a study of 54 participants found no objective performance difference in burnout but greater neural resource allocation to reach it, which is what executive burnout therapy is built to address before the output finally moves.12
Clinical
Measure the lag to care and report it like any other operating number
It was a median of 19 months in this sample, it is knowable, and unlike stigma it can be moved directly. It is also the only variable in this cycle that an individual, a board or a sponsor can shorten this quarter.
Structural
Prefer role-informed individual treatment over population wellness provision
This is a recommendation about matching an intervention to a mechanism, not a claim that therapy is proven superior for this group. The evidence against generic provision is strong and randomised;14 the evidence for any specific alternative in this population is thin, which the burnout literature itself acknowledges.05 Choose on mechanism and say so.
Structural
Quote the prevalence figures honestly or not at all
The circulating CEO burnout numbers are one survey question read at three different cut-points, from a single vendor sampling its own membership.02, 03 A separate and unrelated 71 percent figure about the C-suite, drawn from a survey of 1,050 C-suite leaders, measures intent to change employer rather than burnout, and the two are routinely conflated.08 A paper that reports all of this plainly is more useful to a board than one that repeats the largest available number, and considerably harder to dismiss.
FAQCommon questions§
Where does the 71% figure come from?
Do external surveys really show CEO burnout around 70 percent?
What does concealing burnout from a board actually mean here?
How does private-pay billing work?
How is my privacy protected?
MethodologyHow this paper was built§
Methodology
This Index has two components, reported separately throughout, and in this paper they measure different constructs, so no figure from one is used to support a claim about the other. The clinical component is a review of consecutive senior executive and CEO clients seen through CEREVITY between 1 January 2025 and 31 August 2026. After inclusion criteria were applied, chief executive or equivalent senior responsibility and sufficient clinical contact for the relevant variables to be assessed, 298 clients remained. Variables were recorded from structured intake and clinician-documented review: whether criteria for significant burnout were met on structured assessment, whether the severity had been deliberately withheld from a board, self-rated effect on decision quality, and the interval between clear recognition of the problem and a first clinical session. The external component draws on peer-reviewed research, one intergovernmental classification, commercial survey research and one commercial tracking series, identified through PubMed, Europe PMC, Crossref and Google Scholar and through direct retrieval from publishing organisations, covering 2005 to 2026. Sample sizes and field dates are stated wherever a source is used: Vistage Q2 2025 (n=1,537 US CEOs, fielded 2 to 16 June 2025), the WSJ and Vistage small-business index (n=495, fielded 5 to 12 May 2025), Businessolver 2024 (more than 3,000 employees, HR leaders and CEOs, fielded March 2024, CEO sub-sample size not published), Deloitte and Workplace Intelligence 2024 (n=3,150 including 1,050 C-suite, fielded 26 February to 8 March 2024), Borgschulte and colleagues (1,605 CEOs with hand-collected vital dates), Detert and Edmondson (four studies including 190 interviews), Slepian and colleagues (ten studies, more than 13,000 secrets), Deligkaris and colleagues (15 studies), Pihlaja and colleagues (n=54), Shields and colleagues (34 studies and N=1,353 for working memory, 6 studies and N=280 for cognitive flexibility), Song and Baicker (160 worksites, 32,974 employees, January 2015 to June 2016), Fleming (46,336 workers across 233 organisations), Challenger, Gray and Christmas (2,221 announced CEO departures in 2024) and Wang and colleagues (n=9,282). Limitations are material and several are unusual enough to state individually. The CEREVITY sample is clinical and help-seeking and cannot support a prevalence claim about chief executives generally. The concealment and decision-quality items are self-reported and retrospective, and the effect on decision quality is the executive's own judgement rather than a measured outcome. All available external CEO burnout figures come from vendor surveys of self-selected membership panels; none is a probability sample, and the two Vistage figures come from the same organisation. The Businessolver CEO percentages rest on an unpublished CEO denominator. The Deloitte 71 percent figure concerns intent to change jobs, not burnout, and is cited only as such. Shields and colleagues measures acute laboratory stress rather than chronic occupational burnout, and the effect sizes are small; the inference to chief executive decision quality is a leap and is labelled as one. Deligkaris and colleagues explicitly declines to establish causality. Pihlaja and colleagues found no objective performance difference and is cited for the compensatory cost it did find, not for impairment it did not. Borgschulte and colleagues studies large-firm US CEOs who are overwhelmingly male and White. Fleming is cross-sectional and cannot establish that the interventions do not work, since selection into participation is uncontrolled. The Challenger departure data records stated reasons only and supports no inference about unstated causes. The Wang comparator is a general population figure from a survey fielded in 2001 to 2003, included for scale rather than as a matched control. Several widely quoted CEO burnout statistics were examined for this paper and excluded because no primary methodological source could be located, or because the figure turned out to be a sum computed by a secondary outlet rather than a published result. Nothing here is legal advice or a statement about any disclosure obligation.
References
- 01CEREVITY. (2026). CEO Burnout Index: clinical review of 298 consecutive senior executive and CEO clients, January 2025 to August 2026. Internal clinical data, not publicly posted.
- 02Vistage Worldwide. (2025). CEO confidence continues to cool in Q2 2025 as hiring plans hit an all-time low. Vistage CEO Confidence Index, Q2 2025. n=1,537 US CEOs, fielded 2 to 16 June 2025. Vendor survey of Vistage membership, non-probability sample. vistage.com
- 03Vistage Worldwide and The Wall Street Journal. (2025). Small business confidence rises; costs and tariffs bite margins. WSJ and Vistage Small Business CEO Confidence Index, May 2025. n=495, fielded 5 to 12 May 2025. Vendor survey of Vistage membership, non-probability sample. vistage.com
- 04World Health Organization. (2019). Burn-out an occupational phenomenon: International Classification of Diseases. ICD-11 took effect for national and international reporting in January 2022. who.int
- 05Maslach, C., and Leiter, M. P. (2016). Understanding the burnout experience: recent research and its implications for psychiatry. World Psychiatry, 15(2), 103 to 111. doi.org
- 06Borgschulte, M., Guenzel, M., Liu, C., and Malmendier, U. (2025). CEO stress, aging, and death. The Journal of Finance, 80(6), 3401 to 3442. 1,605 CEOs with hand-collected dates of birth and death. nber.org
- 07Businessolver. (2024). 2024 State of Workplace Empathy: 55% of CEOs say they have experienced a mental health issue. More than 3,000 employees, HR leaders and CEOs, fielded March 2024. CEO sub-sample size not published. businessolver.com
- 08Deloitte and Workplace Intelligence. (2024). The important role of leaders in advancing human sustainability. n=3,150 including 1,050 C-suite leaders, fielded 26 February to 8 March 2024. The 71 percent figure in this source concerns intent to change employer, not burnout. deloitte.com
- 09Detert, J. R., and Edmondson, A. C. (2011). Implicit voice theories: taken-for-granted rules of self-censorship at work. Academy of Management Journal, 54(3), 461 to 488. Four studies, including 190 interviews. hbs.edu
- 10Slepian, M. L., Chun, J. S., and Mason, M. F. (2017). The experience of secrecy. Journal of Personality and Social Psychology, 113(1), 1 to 33. Ten studies, more than 13,000 secrets. columbia.edu
- 11Deligkaris, P., Panagopoulou, E., Montgomery, A. J., and Masoura, E. (2014). Job burnout and cognitive functioning: a systematic review. Work and Stress, 28(2), 107 to 123. 15 studies. The authors explicitly decline to establish causality. researchportal.northumbria.ac.uk
- 12Pihlaja, M., Perakyla, J., Erkkila, E. H., Tapio, E., Vertanen, M., and Hartikainen, K. M. (2023). Altered neural processes underlying executive function in occupational burnout: basis for a novel EEG biomarker. Frontiers in Human Neuroscience, 17, article 1194714. n=54. No objective performance difference was found between groups. pmc.ncbi.nlm.nih.gov
- 13Shields, G. S., Sazma, M. A., and Yonelinas, A. P. (2016). The effects of acute stress on core executive functions: a meta-analysis and comparison with cortisol. Neuroscience and Biobehavioral Reviews, 68, 651 to 668. Working memory 34 studies N=1,353; cognitive flexibility 6 studies N=280. hmlpubs.faculty.ucdavis.edu
- 14Song, Z., and Baicker, K. (2019). Effect of a workplace wellness program on employee health and economic outcomes: a randomized clinical trial. JAMA, 321(15), 1491 to 1501. 160 worksites, 32,974 employees, January 2015 to June 2016. jamanetwork.com
- 15Fleming, W. J. (2024). Employee well-being outcomes from individual-level mental health interventions: cross-sectional evidence from the United Kingdom. Industrial Relations Journal, 55(2), 162 to 182. 46,336 workers across 233 organisations. Cross-sectional, not a trial. wellbeing.hmc.ox.ac.uk
- 16Challenger, Gray and Christmas. (2025). New records set: CEO exits surge post-election in December 2024. CEO Turnover Report, full year 2024, published 30 January 2025. 2,221 announced CEO departures. Commercial tracking series; no formal methodology statement published. challengergray.com
- 17Wang, P. S., Berglund, P., Olfson, M., Pincus, H. A., Wells, K. B., and Kessler, R. C. (2005). Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 603 to 613. n=9,282, fielded February 2001 to April 2003. jamanetwork.com
Licensed Clinical Social Worker
Martha Fernandez, LCSW is Co-Founder of CEREVITY and a Licensed Clinical Social Worker licensed in California, seeing clients by telehealth nationwide through CEREVITY's network of independent licensed clinicians. USC-trained and bilingual in English and Spanish, she works with founders, executives, attorneys and pilots on burnout, anxiety and depression in high performers, on trauma, grief and high-stakes transitions, and on couples and relationship strain under pressure. Her clinical work draws on cognitive behavioral therapy, acceptance and commitment therapy, behavioral activation, and narrative and solution-focused approaches. She is the author of Wired to Burn.
Talk to someone who gets it.
If this paper describes something you recognize, a confidential conversation is the next step. CEREVITY matches you to an independent licensed clinician who works with people in your position.
Schedule consultationPrivate-pay, telehealth, nationwide. Questions: (562) 295-6650